Cempra Inc.’s Solithromycin (CEM-101) Demonstrates In Vitro Activity Against Antibiotic-Resistant Ne – PR-USA.net

The company also intends to utilize its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about …

Leave a Reply

Your email address will not be published. Required fields are marked *